BABIO, a leading Chinese manufacturer of rapid diagnostic tests and clinical consumables, has announced the launch of its upgraded Combo SARS-CoV-2 / Flu A & B / RSV Antigen Rapid Test Kit, designed to meet global demand for fast, reliable respiratory virus detection.

As respiratory infections surge across Europe, the United States, Africa, and Southeast Asia, healthcare facilities are seeking efficient solutions capable of distinguishing between viruses with overlapping symptoms. This multi-target antigen test provides a powerful tool for point-of-care diagnostics, primary care clinics, emergency units, and community testing programs.

The test detects COVID-19, Influenza A, Influenza B, and Respiratory Syncytial Virus (RSV) simultaneously using colloidal gold immunochromatography. Results are available in just 15 minutes, allowing healthcare providers to quickly triage patients and initiate timely infection control measures.

With comprehensive pathogen coverage, ready-to-use components, and high analytical reliability, the kit supports early detection during peak respiratory seasons. BABIO manufactures the product under strict quality control standards to ensure consistent sensitivity and specificity across all batches.

As global health systems enhance surveillance for viral respiratory diseases, BABIO continues to provide high-quality diagnostic solutions trusted by healthcare institutions worldwide.

For more details or OEM/ODM collaboration opportunities, please visit the official website:https://www.babiomed.com

#COVID19Testing#FluTesting#RSVTesting#RapidAntigenTest#RespiratoryVirusTest#PointOfCareTesting#DiagnosticKits#BABIO